BPMC
Price
$97.17
Change
-$1.59 (-1.61%)
Updated
May 9 closing price
Capitalization
6.28B
80 days until earnings call
RARE
Price
$35.11
Change
-$0.87 (-2.42%)
Updated
May 9 closing price
Capitalization
3.32B
81 days until earnings call
Ad is loading...

BPMC vs RARE

Header iconBPMC vs RARE Comparison
Open Charts BPMC vs RAREBanner chart's image
Blueprint Medicines
Price$97.17
Change-$1.59 (-1.61%)
Volume$621.84K
Capitalization6.28B
Ultragenyx Pharmaceutical
Price$35.11
Change-$0.87 (-2.42%)
Volume$1.14M
Capitalization3.32B
BPMC vs RARE Comparison Chart
Loading...
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BPMC vs. RARE commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BPMC is a Buy and RARE is a Buy.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (BPMC: $97.17 vs. RARE: $35.11)
Brand notoriety: BPMC and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BPMC: 59% vs. RARE: 123%
Market capitalization -- BPMC: $6.28B vs. RARE: $3.32B
BPMC [@Biotechnology] is valued at $6.28B. RARE’s [@Biotechnology] market capitalization is $3.32B. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BPMC’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • BPMC’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, BPMC is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BPMC’s TA Score shows that 6 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • BPMC’s TA Score: 6 bullish, 5 bearish.
  • RARE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BPMC is a better buy in the short-term than RARE.

Price Growth

BPMC (@Biotechnology) experienced а -7.14% price change this week, while RARE (@Biotechnology) price change was -10.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

BPMC is expected to report earnings on Jul 30, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BPMC($6.28B) has a higher market cap than RARE($3.32B). BPMC YTD gains are higher at: 11.408 vs. RARE (-16.544). BPMC has higher annual earnings (EBITDA): 19.2M vs. RARE (-469M). BPMC (615M) and RARE (610M) have equal amount of cash in the bank . RARE has less debt than BPMC: RARE (40.3M) vs BPMC (469M). RARE has higher revenues than BPMC: RARE (560M) vs BPMC (509M).
BPMCRAREBPMC / RARE
Capitalization6.28B3.32B189%
EBITDA19.2M-469M-4%
Gain YTD11.408-16.544-69%
P/E RatioN/AN/A-
Revenue509M560M91%
Total Cash615M610M101%
Total Debt469M40.3M1,164%
FUNDAMENTALS RATINGS
BPMC vs RARE: Fundamental Ratings
BPMC
RARE
OUTLOOK RATING
1..100
1313
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
67100
SMR RATING
1..100
9296
PRICE GROWTH RATING
1..100
4760
P/E GROWTH RATING
1..100
57100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (73) in the Biotechnology industry is in the same range as BPMC (80). This means that RARE’s stock grew similarly to BPMC’s over the last 12 months.

BPMC's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for RARE (100). This means that BPMC’s stock grew somewhat faster than RARE’s over the last 12 months.

BPMC's SMR Rating (92) in the Biotechnology industry is in the same range as RARE (96). This means that BPMC’s stock grew similarly to RARE’s over the last 12 months.

BPMC's Price Growth Rating (47) in the Biotechnology industry is in the same range as RARE (60). This means that BPMC’s stock grew similarly to RARE’s over the last 12 months.

BPMC's P/E Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for RARE (100). This means that BPMC’s stock grew somewhat faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BPMCRARE
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CEW18.190.05
+0.27%
WisdomTree Emerging Currency Strat ETF
JMST50.740.03
+0.06%
JPMorgan Ultra-Short Municipal Inc ETF
HYGW30.56-0.03
-0.11%
iShares High Yld Crp Bd Buywrt Stgy ETF
ISCG46.04-0.20
-0.43%
iShares Morningstar Small-Cap Growth ETF
CNBS17.19-0.88
-4.88%
Amplify Seymour Cannabis ETF

BPMC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with ORIC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then ORIC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BPMC
1D Price
Change %
BPMC100%
-1.61%
ORIC - BPMC
43%
Loosely correlated
-4.51%
ELVN - BPMC
42%
Loosely correlated
-1.13%
AXON - BPMC
41%
Loosely correlated
-0.33%
OCUL - BPMC
41%
Loosely correlated
-5.23%
BBIO - BPMC
40%
Loosely correlated
-1.95%
More